Clinical Trial Results:
Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC4493 or EFC6682: a double blind parallel group study comparing satavaptan at 5 to 10 mg daily versus placebo
Summary
|
|
EudraCT number |
2006-006521-30 |
Trial protocol |
NL FR BE SE DE ES IT CZ HU PT DK GB |
Global completion date |
10 Jan 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Nov 2016
|
First version publication date |
17 Nov 2016
|
Other versions |
|
Summary report(s) |
LTS10036 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.